About-cancer / ọgwụgwọ / adakarị-ọnwụnwa / ọrịa / intraocular-melanoma / ọgwụgwọ
Usoro Ọgwụ Ọgwụ Ọrịa Maka Melanoma Intraocular
Ọnwụnwa ụlọ ọgwụ bụ ọmụmụ nyocha metụtara mmadụ. Ọnwụnwa ahụike a dị na ndepụta a bụ maka ọgwụgwọ melanoma intraocular. Ọnwụnwa niile dị na listi ahụ na-akwado NCI.
Ihe omuma nke NCI banyere ule banyere ulo ogwu na akowa udiri udiri na uzo nke ule na otu esi aru ha. Ọnwụnwa ahụike na-eleba anya n'ụzọ ọhụrụ iji gbochie, chọpụta, ma ọ bụ gwọọ ọrịa. Ikwesiri iche echiche banyere isonye na ikpe ogwu. Gwa dọkịta gị ka o nyere gị aka ikpebi ma ọ bụrụ na ọ dị gị mma.
Nnwale 1-25 nke 25
Nchedo na nrụpụta ọrụ nke IMCgp100 na Onye Nchọpụta Nhọrọ na Advanced Uveal Melanoma
Iji nyochaa nlanarị ndụ zuru oke nke HLA-A * 0201 ndị toro eto na-arịa ọrịa nwere UM na-enweghị ọgwụgwọ na-anata IMCgp100 ma e jiri ya tụnyere Choice Choice nke dacarbazine, ipilimumab, ma ọ bụ pembrolizumab.
Ọnọdụ: Ọnọdụ 19
Ihe omumu nke XmAb®22841 Monotherapy & na Nchikota w / Pembrolizumab na Isiokwu w / Họrọ Tumo Tọrọ Egwu
Nke a bụ oge 1, ọtụtụ ọgwụ, ọmụmụ ọmụmụ ihe na-abawanye elu na ọmụmụ mmụba nke ezubere iji kọwaa oke ọgwụ kachasị na / ma ọ bụ ọgwụ akwadoro nke XmAb22841 monotherapy yana yana pembrolizumab; iji nyochaa nchekwa, ndidi, pharmacokinetics, immunogenicity, na mgbochi akpụ ọrụ nke XmAb22841 monotherapy na yana yana pembrolizumab na isiokwu nwere họrọ oke ọkpọ siri ike.
Ọnọdụ: Ọnọdụ 10
Ọmụmụ nke RP1 Monotherapy na RP1 na Nchikota na Nivolumab
RPL-001-16 bụ 1/2 nke oge, akara ngosi, mmụba ọgwụ na mmụba ọmụmụ ihe gbasara RP1 naanị yana yana nivolumab na ndị okenye na-eto eto na / ma ọ bụ etuto ahụ siri ike, iji chọpụta oke ọgwụ edozi (MTD) ma kwadoro usoro nke 2 (RP2D), yana iji nyochaa nrụpụta ọrụ mbido.
Ọnọdụ: Ọnọdụ 6
Ọmụmụ ihe na ndị nwere obere Choroidal Melanoma
Ebumnuche bụ isi bụ iji nyochaa nchekwa, immunogenicity na nrụpụta ọrụ nke otu n'ime usoro onunu ogwu atọ na ikwughachi usoro nke Light-activated AU-011 na otu ma ọ bụ abụọ ngwa laser maka ọgwụgwọ nke isiokwu nwere isi choroidal melanoma.
Ọnọdụ: Ọnọdụ 4
Ọmụmụ banyere IDE196 na Ndị Ọrịa Na-ebu Ọrịa Tumoro Na-ebugharị GNAQ / 11 Mutations ma ọ bụ PRKC Fusions
Nke a bụ 1/2 na-adọ, ọtụtụ-etiti, ọmụmụ ihe nkata na-emeghe iji nyochaa nchekwa na mgbochi akpụ nke ọrụ IDE196 na ndị ọrịa nwere akpụ siri ike na-ebugharị mgbanwe GNAQ ma ọ bụ GNA11 (GNAQ / 11) ma ọ bụ njikọ PRKC, gụnyere metastatic uveal melanoma (MUM), cutanous melanoma, colorectal cancer, na etuto ndị ọzọ siri ike. Oge 1 (mmụba ọgwụ) ga-enyocha nchekwa, ndidi na ọgwụcokinetics nke IDE196 site na usoro mmụba ọgwụ na-edozi ma chọpụta usoro ọgwụ 2 na-atụ aro. A ga-enyocha ọrụ nchekwa na mgbochi tumo na Usoro nke 2 (mmụba dose) nke ọmụmụ ihe.
Ọnọdụ: Ọnọdụ 4
Selumetinib Sulfate na-agwọ ndị ọrịa nwere Uveal Melanoma ma ọ bụ GNAQ / GNA11 Melanoma Mutated Nke Metastatic ma ọ bụ enweghị ike wepu ya n'ịwa ahụ
Usoro ikpe a nke Ib na-amụ mmetụta na ọgwụ kachasị mma nke selumetinib sulfate na ịgwọ ndị ọrịa na uveal melanoma ma ọ bụ GNAQ / GNA11 melanoma gbasasịrị nke sitere na saịtị mbụ gaa ebe ndị ọzọ na ahụ ma ọ bụ enweghị ike wepu ya site na ịwa ahụ. Selumetinib sulfate nwere ike ịkwụsị uto nke mkpụrụ ndụ tumo site na igbochi ụfọdụ enzymes dị mkpa maka uto sel.
Ọnọdụ: Ọnọdụ 3
VSV-IFNbetaTYRP1 a gbanwere na Ngwọta Ọrịa na Nkeji III-IV Melanoma
Akụkụ nke mbụ a na-eme ka m mata ọmụmụ ihe na ọgwụ kachasị mma nke nje a na-akpọ VSV-IFNbetaTYRP1 n'ịgwọ ndị ọrịa nwere usoro III-IV melanoma. A gbanwere nje vesicular stomatitis (VSV) iji tinye mkpụrụ ndụ ihe nketa abụọ: mmadụ interferon beta (hIFNbeta), nke nwere ike ichebe sel ndị ahụike dị mma ka ha ghara ibute nje ahụ, yana TYRP1, nke gosipụtara tumadi na melanocytes na - eweputa ihe na - egbochi akpụkpọ melanin na - acha uhie uhie na - egbochi melanoma), yana nwere ike ịkpalite mmeghachi omume siri ike iji gbuo mkpụrụ ndụ akpụ melanoma.
Ọnọdụ: Ọnọdụ 2
Ọmụmụ nke PLX2853 na Advanced Malignancies.
Ebumnuche nke ọmụmụ ihe a bụ iji nyochaa nchekwa, ọgwụcokinetics, pharmacodynamics na mbido nrụpụta nke ọgwụ nyocha PLX2853 na isiokwu ndị nwere ajọ nsogbu.
Ọnọdụ: Ọnọdụ 2
Yttrium90, Ipilimumab, & Nivolumab maka Uveal Melanoma Na Imeju Metastases
Akụkọ na-egosi na nrụpụta dị ukwuu nke usoro ọgwụgwọ ọrịa maka uveal melanoma. Ihe omumu na ihe omumu nke oge a na-egosi nchikota n'etiti ogwu radieshon na immunotherapy. Ndị nchọpụta ahụ ga-enyocha mmekọrịta a na ọmụmụ ihe nke ndị ọrịa 26 nwere uveal melanoma na metastases hepatic bụ ndị ga-anata SirSpheres Yttrium-90 na-ahọrọ ọnya ọgbụgba na-esote na immunotherapy na ipilimumab na nivolumab.
Ọnọdụ: Ọnọdụ 2
Pegargiminase, Nivolumab na Ipilimumab na-agwọ ndị ọrịa nwere Uveal Melanoma nke dị elu ma ọ bụ nke na-enweghị ike ịgbanwe
Usoro nke a nke m na-amụ mmetụta nke pegargiminase, nivolumab na ipilimumab n'ịgwọ ndị ọrịa na uveal melanoma nke gbasaa na ebe ndị ọzọ na ahụ (dị elu) ma ọ bụ enweghị ike wepu ya site na ịwa ahụ (enweghị ike ịkọwa). Pegargiminase nwere ike ịkwụsị uto nke mkpụrụ ndụ tumo site na igbochi ụfọdụ enzymes dị mkpa maka uto mkpụrụ ndụ. Immunotherapy na monoclonal antibodies, dị ka nivolumab na ipilimumab, nwere ike inyere usoro ahụ ji alụso ọrịa ọgụ ọgụ megide kansa, ma nwee ike igbochi ikike nke mkpụrụ ndụ tumo na-eto ma gbasaa. Inye pegargiminase, nivolumab na ipilimumab nwere ike ịka mma ma e jiri ya tụnyere immunotherapy naanị.
Ọnọdụ: Ebe Ncheta nke Sloan Kettering Cancer Center, New York, New York
Stereotactic Isi Radiation Agwọ na Aflibercept na-emeso Ndị Ọrịa na Uveal Melanoma
Usoro ihe omuma nke abuo a na achoputa uzo ogwu nke aru na aru oru na igha ndi oria uveal melanoma. Usoro ọgwụgwọ radieshon nke Stereotactic na-eji akụrụngwa pụrụ iche iji dozie onye ọrịa ma nyefee radieshon na etuto ahụ nwere oke nkenke. Usoro a nwere ike igbu mkpụrụ ndụ tumọ na obere doses n'oge dị mkpirikpi ma kpatara obere mmebi anụ ahụ nkịtị. Aflibercept nwere ike ịkwụsị uto nke mkpụrụ ndụ tumo site na igbochi ụfọdụ enzymes dị mkpa maka uto sel. Inye usoro ọgwụgwọ radieshon ahụ nke na-esochi aflibercept nwere ike ịrụ ọrụ nke ọma n'ịgwọ ndị ọrịa nwere uveal melanoma.
Ọnọdụ: Jefflọ Ọgwụ Mahadum Thomas Jefferson, Philadelphia, Pennsylvania
Ọmụmụ Ihe Nchedo na Ndagide nke INCAGN02390 na Họrọ Advanced Malignancies
Ebumnuche nke ọmụmụ a bụ iji chọpụta nchekwa, ndidi, na nrụpụta mmalite nke INCAGN02390 na ndị sonyere na-ahọrọ nsogbu na-adịghị mma.
Ọnọdụ: Hackensack University Medical Center, Hackensack, New Jersey
Mgbochi (6MHP) na ma ọ bụ na-enweghị CDX-1127 maka ọgwụgwọ nke ọkwa IIB-IV Melanoma
Usoro ikpe a nke I / II na-amụ mmetụta na etu ogwu (6MHP) nwere ma ọ bụ na-enweghị CDX-1127 na-arụ ọrụ maka ọgwụgwọ nke ọkwa IIB-IV melanoma. Ọgwụ mgbochi, dị ka 6MHP, nwere ike inyere ahụ aka ịme nzaghachi dị irè iji gbuo mkpụrụ ndụ tumo. Immunotherapy na monoclonal-alụso ọrịa ọgụ, dị ka CDX-1127, nwere ike inyere usoro ahụ ji alụso ọrịa ọgụ ọgụ megide kansa, ma nwee ike igbochi ike mkpụrụ ndụ tumo na-eto ma gbasaa. A na-eme ikpe a iji hụ ihe mmetụta 6MHP naanị yana yana CDX-1127 nwere na mgbanwe na usoro ahụ ji alụso ọrịa ọgụ.
Ọnọdụ: Mahadum nke Virginia Cancer Center, Charlottesville, Virginia
Ipilimumab na Nivolumab nwere Immunoembolization na Treatgwọ Ndị Ọrịa na Uveal Melanoma Metastatic
Usoro ihe ọmụmụ nke abụọ a na - amụ ipilimumab na nivolumab na immunoembolization na ịgwọ ndị ọrịa nwere uveal melanoma nke gbasaa na imeju. Immunotherapy na monoclonal antibodies, dị ka ipilimumab na nivolumab, nwere ike inyere usoro ahụ ji alụso ọrịa ọgụ ọgụ megide kansa, ma nwee ike igbochi ikike nke mkpụrụ ndụ tumo na-eto ma gbasaa. Immunoembolization nwere ike igbu mkpụrụ ndụ tumo n'ihi enweghị ọbara na-ebute nzaghachi mgbochi megide mkpụrụ ndụ tumo. Inye ipilimumab na nivolumab na immunoembolization nwere ike ịrụ ọrụ nke ọma n'ịgwọ ndị ọrịa nwere uveal melanoma.
Ọnọdụ: Jefflọ Ọgwụ Mahadum Thomas Jefferson, Philadelphia, Pennsylvania
Cyclophosphamide, Fludarabine, Tumor na-abanye Lymphocytes, na Aldesleukin na-emeso ndị so na Metastatic Uveal Melanoma
Oge ikpe nke abụọ a na-amụ etu cyclophosphamide, fludarabine, tumor infiltrating lymphocytes, na aldesleukin na-arụ ọrụ n'ịgwọ ndị sonyere na uveal melanoma nke gbasaa na ebe ndị ọzọ. Ọgwụ ndị a na-eji na chemotherapy, dị ka cyclophosphamide na fludarabine, na-arụ ọrụ n’ụzọ dị iche iche iji kwụsị uto nke mkpụrụ ndụ etuto, ma ọ bụ site n’igbu mkpụrụ ndụ, site n’ime ka ha ghara ikewa, ma ọ bụ site n’ime ka ha ghara ịgbasa. Tumor na-abanye lymphocytes nwere ike ịbụ ọgwụgwọ dị irè maka uveal melanoma. Aldesleukin nwere ike kpalite mkpụrụ ndụ ọbara ọcha iji gbue mkpụrụ ndụ melanoma uveal. Inye cyclophosphamide, fludarabine, tumo infiltrating lymphocytes, na aldesleukin nwere ike igbu ọtụtụ akpụ mkpụrụ ndụ.
Ọnọdụ: Mahadum nke Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Autologous CD8 + SLC45A2-Specific T Lymphocytes na Cyclophosphamide, Aldesleukin, na Ipilimumab na-emeso ndị so na Metastatic Uveal Melanoma
Usoro ikpe a nke Ib na-amụ mmetụta na ọgwụ kachasị mma nke CD8 autologous (+) SLC45A2-kpọmkwem T lymphocytes mgbe e nyere ya na cyclophosphamide, aldesleukin, na ipilimumab, na iji hụ otu ha si arụ ọrụ n'ịgwọ ndị sonyere na uveal melanoma nke gbasaa gaa ebe ndị ọzọ na ahụ. Iji mee sel CD8 + T pụrụ iche, ndị na-eme nchọpụta kewapụrụ mkpụrụ ndụ T nke anakọtara site na ọbara onye na-emeso ha ma gwọọ ha ka ha nwee ike leba anya na mkpụrụ ndụ melanoma. A na-enyeghachi onye so na ya mkpụrụ ndụ ọbara. A maara nke a dị ka "onye na-anabata T cell transfer" ma ọ bụ "onye na-agbakwunye T cell therapy." Ọgwụ ndị a na-eji na chemotherapy, dị ka cyclophosphamide, nwere ike ịrụ ọrụ n'ụzọ dị iche iche iji kwụsị uto nke mkpụrụ ndụ etuto, site na igbu mkpụrụ ndụ, site na ịkwụsị ha nkewa, ma ọ bụ site na ịkwụsị ha ịgbasa. Usoro ọgwụgwọ ndu, dị ka aldesleukin, jiri ihe ndị sitere na ihe ndị dị ndụ nwere ike ime ka usoro ahụ ji alụso ọrịa ọgụ dị iche iche ma gbochie mkpụrụ ndụ etuto ahụ. Immunotherapy na monoclonal-alụso ọrịa ọgụ, dị ka ipilimumab, nwere ike inyere usoro ahụ ji alụso ọrịa ọgụ ọgụ megide cancer, na nwere ike igbochi ike nke akpụ mkpụrụ ndụ na-eto eto na-agbasa. Inye CD8 + SLC45A2-kpọmkwem T lymphocytes yana cyclophosphamide, aldesleukin, na ipilimumab nwere ike ịrụ ọrụ nke ọma n'ịgwọ ndị sonyere na uveal melanoma metastatic.
Ọnọdụ: MD Anderson Cancer Center, Houston, Texas
Intravenous na Intrathecal Nivolumab na inggwọ Ndị Ọrịa na Ọrịa Leptomeningeal
Usoro ikpe a nke I / Ib na-amụ mmetụta na mkpụrụ ọgwụ kachasị mma nke intrathecal nivolumab, yana otu o si arụ ọrụ nke ọma yana intravenous nivolumab n'ịgwọ ndị ọrịa nwere ọrịa leptomeningeal. Immunotherapy na monoclonal na-alụso ọrịa ọgụ, dị ka nivolumab, nwere ike inyere usoro ahụ ji alụso ọrịa ọgụ ọgụ megide kansa, ma nwee ike igbochi ike mkpụrụ ndụ tumo na-eto ma gbasaa.
Ọnọdụ: MD Anderson Cancer Center, Houston, Texas
Nivolumab nwere ma ọ bụ na-enweghị Ipilimumab ma ọ bụ Relatlimab tupu ịwa ahụ na ịgwọ ndị ọrịa nwere ọkwa IIIB-IV Melanoma Nke Nwere Ike bywa Ahụ
Usoro ikpe a nke usoro nke abụọ na-amụ ihe nke ọma nivolumab nwere ma ọ bụ na-enweghị ipilimumab ma ọ bụ relatlimab tupu ịwa ahụ na-arụ ọrụ n'ịgwọ ndị ọrịa nwere IIIB-IV melanoma nke nwere ike wepụ ịwa ahụ. Immunotherapy na ọgwụ nje monoclonal, dị ka nivolumab, ipilimumab, na relatlimab, nwere ike inyere usoro ahụ ji alụso ọrịa ọgụ ọgụ megide kansa, ma nwee ike igbochi ikike nke mkpụrụ ndụ tumo na-eto ma gbasaa. Inye nivolumab naanị ya ma ọ bụ yana ipilimumab ma ọ bụ relatlimab tupu ịwa ahụ nwere ike ime ka etuto ahụ pere mpe ma belata ọnụ ọgụgụ nke anụ ahụ kwesịrị ka ewepụ.
Ọnọdụ: MD Anderson Cancer Center, Houston, Texas
6MHP Vaccine na Ipilimumab na-agwọ ndị ọrịa nwere ọkwa IIA-IV Melanoma
Usoro ihe a I / II nke a na-amụ mmetụta nke 6 melanoma helper peptide ogwu (6MHP) na ipilimumab na iji hụ etu ha si arụ ọrụ n'ịgwọ ndị ọrịa nwere IIA-IV melanoma. Ọgwụ emere site na peptides, dị ka ọgwụ mgbochi 6MHP, nwere ike inyere ahụ aka ịme nzaghachi dị irè iji gbuo mkpụrụ ndụ tumo. Immunotherapy na monoclonal-alụso ọrịa ọgụ, dị ka ipilimumab, nwere ike inyere usoro ahụ ji alụso ọrịa ọgụ ọgụ megide cancer, na nwere ike igbochi ike nke akpụ mkpụrụ ndụ na-eto eto na-agbasa. Amabeghị ma ịnye ọgwụ mgbochi 6MHP na ipilimumab na-arụ ọrụ nke ọma n'ịgwọ ndị ọrịa nwere melanoma.
Ọnọdụ: Mahadum nke Virginia Cancer Center, Charlottesville, Virginia
Dabrafenib Mesylate, Trametinib, na 6 Melanoma Inyeaka Ọrịa Peptide na-agwọ Ndị Ọrịa na Nkeji IIIB-IV Melanoma
Oge ikpeazu I / II nke a na-amụ mmetụta ndị ahụ na etu dabrafenib mesylate, trametinib, na 6 melanoma helper peptide ogwu na-arụ ọrụ n'ịgwọ ndị ọrịa nwere ọkwa IIIB-IV melanoma. Dabrafenib mesylate na trametinib nwere ike ịkwụsị uto nke mkpụrụ ndụ tumo site na igbochi ụfọdụ enzymes dị mkpa maka uto mkpụrụ ndụ. Ọgwụ mgbochi, dị ka ọgwụ mgbochi peptide na-enyere melanoma 6, emere site na peptides nke sitere na protein melanoma, nwere ike inyere ahụ aka ịmalite nzaghachi na-enweghị isi iji gbuo mkpụrụ ndụ tumo nke na-egosipụta antigens melanoma-kpọmkwem. Inye dabrafenib, trametinib, na 6 melanoma inyeaka peptide ogwu nwere ike ịrụ ọrụ nke ọma n'ịgwọ ndị ọrịa nwere melanoma.
Ọnọdụ: Mahadum nke Virginia Cancer Center, Charlottesville, Virginia
Sunitinib Malate ma ọ bụ Valproic Acid na igbochi metastasis na ndị ọrịa nwere nnukwu ihe egwu Uveal Melanoma
Usoro nyocha nke II nke a na-enweghị usoro na-amụ otú sunitinib malate ma ọ bụ valproic acid si arụ ọrụ nke ọma iji gbochie melanoma uveal dị elu (anya) ịgbasa n'akụkụ ndị ọzọ. Sunitinib malate nwere ike ịkwụsị nnyefe nke ihe ngosi ibu n'ime sel etuto ma gbochie mkpụrụ ndụ ndị a ka ha ghara ito. Valproic acid nwere ike ịgbanwe ngosipụta nke ụfọdụ mkpụrụ ndụ ihe nketa na uveal melanoma ma gbochie uto tumo.
Ọnọdụ: Jefflọ Ọgwụ Mahadum Thomas Jefferson, Philadelphia, Pennsylvania
Tumor na-abanye Lymphocytes na High-Dose Aldesleukin na ma ọ bụ na-enweghị Autologous Dendritic Sel na Treatgwọ Ndị Ọrịa na Metastatic Melanoma
Usoro ikpe a nke usoro nke II na-amụ ihe banyere ọgwụgwọ ọgwụgwọ na-emetụta lymphocytes na ọgwụ dị elu aldesleukin na ma ọ bụ na-enweghị sel dendritic autologous na-arụ ọrụ n'ịgwọ ndị ọrịa nwere melanoma nke gbasaa n'akụkụ ndị ọzọ nke ahụ. Ọgwụ mgbochi emere site na sel etuto mmadụ na sel ọbara pụrụ iche (sel dendritic) nwere ike inyere ahụ aka wulite mmeghachi omume dị irè iji gbuo mkpụrụ ndụ akpụ. Aldesleukin nwere ike kpalite mkpụrụ ndụ ọbara ọcha iji gbuo mkpụrụ ndụ etuto. Amabeghị ma akpụ ọgwụ na-abanye lymphocytes na ọgwụ dị elu aldesleukin na-arụ ọrụ nke ọma mgbe e nyere ya ma ọ bụ na-enweghị sel dendritic na mbenata ma ọ bụ belata uto nke melanoma. Ihe nlekọta ahụike nke ịnweta ọnya infiltrating lymphocytes (TIL) yana B-Raf proto-oncogene, A ga-amụrụ onye na-egbochi serine / threonine kinase (BRAF), na ndị ọrịa nwere ọrịa na-aga n'ihu (PD) site na iji onye na-egbochi BRAF tupu ọgwụgwọ TIL. Ọrịa Leptomeningeal (LMD) dị mwute ikwu na ọ bụ mmepe nkịtị na-arịa ndị ọrịa nwere melanoma, na-enwe amụma dị oke njọ, na-atụgharị gaa na mkpokọta izu naanị. N'iji usoro eji agwakọta intrathecal TILs na intrathecal interleukin (IL) -2, ndị na-eme nchọpụta nwere olile anya ime ka nsogbu ọrịa ogologo oge ma ọ bụ mgbaghara nke LMD dị.
Ọnọdụ: MD Anderson Cancer Center, Houston, Texas
Vorinostat maka ọgwụgwọ nke klas 2 nnukwu ihe egwu Uveal Melanoma
Oge izizi nke mbụ m na-amụ banyere etu vorinostat si arụ ọrụ n'ịgwọ ndị ọrịa nwere uveal (anya) melanoma. Ndị nchọpụta na-achọpụta na mkpụrụ ndụ ndị dị na uveal melanomas na-akasị ụzọ abụọ: klas 1 na klaasị 2. Klas nke abụọ nke klas na-enwe ohere dị elu nke ịkwaga n'akụkụ ndị ọzọ na ahụ, ebe sel nke klas 1 na-anọkarị na anya. Vorinostat nwere ike ịgbanwe sel abụọ nke klaasị n'ime sel ndị na - eme ihe ike karịa site na "ịgbanye" mkpụrụ ndụ ihe nketa dị na sel nke na-egbochi etuto ahụ.
Ọnọdụ: Mahadum nke Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Ulixertinib na-agwọ ndị ọrịa nwere ọkwa IV Uveal Melanoma
Usoro ikpe a nke II na-amụ mmetụta nke ulixertinib na otu o si arụ ọrụ nke ọma n'ịgwọ ndị ọrịa nwere ọkwa IV uveal melanoma. Ulixertinib nwere ike ịkwụsị uto nke mkpụrụ ndụ tumo site na igbochi ụfọdụ enzymes dị mkpa maka uto mkpụrụ ndụ.
Ọnọdụ: Lee Clinical Trials.gov
Vorinostat na-agwọ ndị ọrịa na Melanoma nke Metastatic nke Anya
Usoro nyocha nke abụọ a na-amụ etu vorinostat si arụ ọrụ n'ịgwọ ndị ọrịa nwere melanoma nke anya gbasaa n'akụkụ ndị ọzọ. Vorinostat nwere ike ịkwụsị uto nke mkpụrụ ndụ tumo site na igbochi ụfọdụ enzymes dị mkpa maka uto sel.
Ọnọdụ: Lee Clinical Trials.gov
